BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

Adding the drug enzalutamide to standard hormone therapy reduced the risk of premature death by more than 40% in patients ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

The United States Prostate Cancer Biomarkers Market is projected to grow from $1.48 billion in 2024 to $3.54 billion by 2033, ...

Men with suspected prostate cancer will be able to get a diagnosis on the NHS within a day, under “game-changing” new trials.

Some 17 million Americans are living with genetic mutations tied to an increased risk of getting cancer, Cleveland Clinic ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 1b clinical study ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...